The focus of my research is disordered mineral metabolism across the spectrum of chronic kidney disease, including dialysis, kidney transplantation and earlier stages.
My research has been published in leading general medicine and subspecialty journals, including the New England Journal of Medicine, JAMA, the Journal of Clinical Investigation, Circulation, Cell Metabolism, Journal of the American Society of Nephrology, and Kidney International, among others.
My primary contributions have been in the area of hormonal regulation of phosphate homeostasis. I have helped to characterize the physiological role of fibroblast growth factor 23 in health and in chronic kidney disease, and the impact of elevated fibroblast growth factor 23 levels on adverse clinical outcomes in patients with kidney disease.
Education and Training
- Research Fellowship in Nephrology, Massachusetts General Hospital, 2000 - 2001
- Clinical Fellowship in Nephrology, Brigham and Women's Hospital, 1999 - 2000
- Internal Medicine Residency, Massachusetts General Hospital, 1996 - 1999
- M.Med.Sc., Harvard Medical School, 2002
- M.D., State University of New York, Brooklyn, 1996
- Novel Mechanisms and Therapeutic Targets for Pulmonary Hypertension in End-Stage Renal Disease (K23)
- JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
- Diet and Hypertension Management in Chronic Kidney Disease
- Endocrinology and Metabolism Training Program
- Metabolic regulation of pancreatitis
- "HiLo": Pragmatic trial of higher vs. lower serum phosphate targets in patients undergoing hemodialysis
- Duke CTSA (TL1)
- The Role of Klotho and Serotonin in Cardiovascular Outcomes and Mortality in CKD
- Duke Training Grant in Nephrology
- Postdoctoral Training in Genomic Medicine Research
- Targeting anti-ferroptotic pathways to prevent the AKI-to-CKD transition